US equities
|
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
ImmunityBio, Inc. - Common Stock
(NQ:
IBRX
)
9.690
-0.690 (-6.65%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ImmunityBio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
ImmunityBio Inc (NASDAQ:IBRX) Q1 Revenue Beat Overshadowed by Wider Losses and Stock Decline
↗
May 07, 2026
Via
Chartmill
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million
May 07, 2026
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
May 06, 2026
From
SkyMedia, LLC
Via
GlobeNewswire
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights
May 06, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc. (NASDAQ: IBRX) on May 26, 2026
May 06, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc. (NASDAQ: IBRX) on May 26, 2026
May 06, 2026
NEW YORK, NY - May 6, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) on...
Via
TheNewswire.com
Topics
Fraud
Lawsuit
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
May 05, 2026
From
Kahn Swick & Foti, LLC
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
May 05, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR DEADLINE ALERT: ImmunityBio, Inc. (IBRX) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
May 05, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
INVESTOR DEADLINE ALERT: ImmunityBio, Inc. (IBRX) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
May 05, 2026
Did you buy IBRX securities between January 19, 2026, and March 24, 2026?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 05, 2026
From
Schall Law
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)
May 05, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting
May 05, 2026
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio, Inc. Class Action Lawsuit: Investors Face May 26, 2026, Deadline
May 01, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
ImmunityBio, Inc. Class Action Lawsuit: Investors Face May 26, 2026, Deadline
May 01, 2026
Did you buy IBRX securities between January 19, 2026, and March 24, 2026?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
May 01, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 01, 2026
From
Schall Law
Via
GlobeNewswire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
April 30, 2026
From
SkyMedia, LLC
Via
GlobeNewswire
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline
April 30, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.
April 29, 2026
From
Robbins LLP
Via
Business Wire
NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc.
April 29, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc.
April 29, 2026
Did you buy IBRX securities between January 19, 2026, and March 24, 2026?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
April 29, 2026
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
April 28, 2026
From
Kahn Swick & Foti, LLC
Via
GlobeNewswire
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
April 28, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
April 28, 2026
Did you buy IBRX securities between January 19, 2026, and March 24, 2026?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
April 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
April 28, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 28, 2026
From
Schall Law
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)
April 28, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
